ERS Genomics has announced the appointment of Jon Kratochvil as VP for Business Development & Licensing for North America.
With more than 30 years of experience, Jon will be a core member of ERS’ global team. Jon joins ERS from MilliporeSigma where he was Director of Business Development and Licensing, with responsibility for all global development opportunities for the company’s gene editing and novel modalities technologies. In his role as Business Development Director for Washington University Jon was pivotal in generating more than $70 m in revenue. Prior to this he was a Licensing Manager and the Competitive Intelligence Analyst for Abbott Laboratories diagnostics division, working on novel detection platforms and pharmacogenetics.
“Jon has a fantastic track record in the industry; we are delighted to welcome him to the team. He will be an asset in our global expansion efforts and pivotal in expanding the use and adoption of CRISPR/Cas9 in North America,” said Eric Rhodes, CEO, ERS Genomics.
“The team at ERS is making huge progress in its mission to increase global access to the Nobel Prize winning CRISPR/Cas9 system,” commented Kratochvil, VP for Business Development & Licensing for North America, ERS Genomics. “This powerful technology has led to a revolution in genetic engineering and I look forward to being part of the next phase.”
